Abcam to acquire BioVision for $340m
Life sciences tool provider Abcam plc has entered into a definitive agreement to acquire BioVision, Inc. for $340m.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1247 entries already.
Entries by Thomas Gabrielczyk
Byondis and Glycotope merge platforms to target carbohydrates
/in News/by Thomas GabrielczykCancer and autoimmunity specialist Byondis BV and carbohydrate-targeting antibody company Glycotope have entered into a platform access agreement.
Artios Pharma Ltd raises US-$153m Series C financing
/in News/by Thomas GabrielczykCancer specialist Artios Pharma has raised $153m in a Series C Financing led by Omega Funds and TCG X to progress its clinical pipeline.
AXA IM Alts raises 1.9bn European Life Sciences Fund
/in News/by Thomas GabrielczykAXA IM Alts has raised 1.9bn of equity to accelerate investments into the Life Sciences sector.
Synaffix inks $246m deal with ProfoundBio
/in News/by Thomas GabrielczykSynaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal
Stada und Calliditas Therapeutics in 97,5 Mio. Euro-Deal
/in News/by Thomas GabrielczykDie Stada Arzneimittel AG zahlt im Rahmen eines EU-Marketingabkommens für Nefecon zur Behandlung der IgA-Nephropathie vorab 20 Mio. Euro an die Calliditas Therapeutics AB.
Nanosyrinx raises £6.2m to validate drug delivery platform
/in News/by Thomas GabrielczykCoventry-based NanoSyrinx plc has raised £6.2m in seed financing to develop a new cell engineering tool for novel targeted therapeutic modalities.
Unilever licences Arzeda Inc.s enzyme technology
/in News/by Thomas GabrielczykAs part of its ‘Clean Future’ strategy, Unilever NV has licensed enzyme technology from Arzeda Inc. to help rid detergent production of fossil carbon.
Bio-Me raises NOK10m
/in News/by Thomas GabrielczykOslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round.
Novalis Biotech closes biotech fund at 25m
/in News/by Thomas GabrielczykEarly-stage venture capital investor Novalis Biotech has closed its Biotech Acceleration Fund at 25m to drive growth of translational medicine start-ups.